Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
BASKING RIDGE, N.J., July 17, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today a program with UpScript, a digital healthcare platform, offering a direct-to-patient telemedicine option for gammaCore™ non-invasive vagus nerve
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
Data from ACT2 Clinical Trial of gammaCore ® in Cluster Headache Presented for First Time Yesterday During Emerging Science Session Basking Ridge, NJ, April 26, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement,
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham Basking Ridge, NJ, September 11, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results
Basking Ridge, New Jersey: ElectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016. Desitin,
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
Investment to fund commercialization of gammaCore ® and further clinical development of nVNS Basking Ridge, NJ, November 29, 2017 – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced
BASKING RIDGE, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ non-invasive vagus
Regulatory clearance marks most recent achievement in new device being available to the approximately 400,000 Americans living with episodic cluster headaches Basking Ridge, NJ, June 15, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
BASKING RIDGE, N.J. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) for an expanded label for gammaCore™ [non-invasive vagus
